News Payday for AbbVie as Humira biosimilar delayed for five year... Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News Roche under pressure as second rituximab biosimilar filed in... Sandoz is following closely behind rival from Teva and Celltrion.
News Ready to pounce: Samsung joins Amgen with Humira biosimilar ... No-one can launch biosimilars until patent expires next year
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
News Ablynx and Sanofi sign potential 2.4bn euro R&D deal Collaboration will develop drugs for inflammatory diseases
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
